MARKET

IMV

IMV

IMV Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.770
-0.020
-0.72%
Closed 16:00 04/16 EDT
OPEN
2.780
PREV CLOSE
2.790
HIGH
2.840
LOW
2.720
VOLUME
99.52K
TURNOVER
--
52 WEEK HIGH
6.82
52 WEEK LOW
1.660
MARKET CAP
187.56M
P/E (TTM)
-6.1000
1D
5D
1M
3M
1Y
5Y
IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV's executive management team will be participating in the 2021 Bloom Burton & Co. Healthcare Investor Virtual Conference which will be held April 20 and Apri...
BusinessWire · 5d ago
Do Options Traders Know Something About IMV Stock We Don't?
Zacks.com · 04/09 12:30
Is IMV (TSE:IMV) A Risky Investment?
Simply Wall St. · 04/08 10:30
IMV to advance its lead asset with Keytruda in mid-stage blood cancer study
Following the feedback from the FDA, IMV ([[IMV]] -2.2%) in agreement with Merck ([[MRK]] +0.4%) is set to evaluate maveropepimut-S (DPX-Survivac) in combination with Keytruda in recurrent/refractory diffuse large B cell
Seekingalpha · 04/07 14:08
H.C. Wainwright Keeps a Buy Rating on IMV (IMV)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV (IMV) today and set a price target of $13.00. The company's shares closed last
SmarterAnalyst · 04/07 13:25
IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma Patients
Benzinga · 04/07 12:54
HYLN, SOS among premarket gainers
SOS (SOS) +36%.Titan Medical (TMDI) +25%.CBAK Energy Technology (CBAT) +21%.Altimeter Growth (AGCUU) +18%.CA Healthcare Acquisition (CAHCU) +16%.TransMedics (TMDX) +16%. as FDA Advisory Panel has issued a favorable vote in support
Seekingalpha · 04/07 12:31
IMV Announces Company-Sponsored Clinical Trial In Patients With r/rDLBCL In Collaboration With Merck Following Feedback From FDA
The two companies agreed on final design of the new Phase 2B study Patient population and clinical endpoints aligned with FDA guidance for potential path to accelerated approval IMV Inc. (NASDAQ:IMV, TSX:IMV)
Benzinga · 04/07 11:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMV. Analyze the recent business situations of IMV Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMV stock price target is 8.85 with a high estimate of 13.10 and a low estimate of 5.04.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 10.48M
% Owned: 15.47%
Shares Outstanding: 67.71M
TypeInstitutionsShares
Increased
12
680.75K
New
8
525.49K
Decreased
7
474.72K
Sold Out
7
4.42M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About IMV
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.

Webull offers kinds of Imv Inc stock information, including NASDAQ:IMV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMV stock methods without spending real money on the virtual paper trading platform.